文献速递冠心病心律失常

美国心脏协会科学声明:心导管室在院外心脏骤停患者管理中的演变角色

The Evolving Role of the Cardiac Catheterization Laboratory in the Management of Patients With Out-of-Hospital Cardiac Arrest: A Scientific Statement From the American Heart Association.
PubMed 文献 · Circulation · 2019-01-01

该科学声明综述了院外心脏骤停(OHCA)患者中冠心病的患病率及其在不同心电图表现下的差异,并描述了基于现有证据的先进灌注/再灌注技术(包括静脉-动脉体外膜氧合)的新兴治疗范式。声明指出,室颤/无脉性室速OHCA且复苏后心电图ST段抬高者冠心病患病率为70%至85%,而无ST段抬高者为25%至50%;早期进入心导管室与功能良好生存率绝对提高10%至15%相关。

要点

  • 室颤/无脉性室速OHCA且复苏后ST段抬高者冠心病患病率70%至85%,多数可成功行PCI。
  • 无ST段抬高者冠心病患病率25%至50%,早期导管室接入与功能良好生存率绝对提高10%至15%相关。
  • 对标准治疗无效的室颤/无脉性室速OHCA,静脉-动脉ECMO联合冠脉造影和PCI的策略在观察性研究中功能良好生存率为9%至45%。

核心结论

  • 室颤/无脉性室速OHCA患者应被视为急性冠脉综合征 continuum 中最高危人群,其冠心病和急性冠脉血栓事件负担显著。
  • 随机试验证据将进一步明确最佳临床实践。

研究设计与样本

  • 美国心脏协会科学声明,基于现有证据综述OHCA患者中冠心病的患病率及治疗范式。
  • 当前科学证据主要基于观察性病例系列,存在潜在混杂选择偏倚;随机临床试验尚在计划或进行中。

主要发现

  • 室颤/无脉性室速OHCA且复苏后心电图ST段抬高者,冠心病患病率为70%至85%,其中超过90%的患者成功接受经皮冠状动脉介入治疗。
  • 室颤/无脉性室速OHCA且复苏后心电图无ST段抬高者,冠心病患病率为25%至50%。
  • 对于无ST段抬高患者,早期进入心导管室与较保守的晚期或不进入心导管室策略相比,功能良好生存率绝对提高10%至15%。
  • 对标准治疗无效的室颤/无脉性室速OHCA患者,采用静脉-动脉体外膜氧合辅助正常灌注恢复并支持进一步复苏(包括冠脉造影和PCI)的新治疗范式,观察性研究中功能良好生存率为9%至45%。

关键数值与推荐

  • 室颤/无脉性室速OHCA且复苏后ST段抬高:冠心病患病率70%至85%,超过90%成功行PCI。
  • 室颤/无脉性室速OHCA且复苏后无ST段抬高:冠心病患病率25%至50%,早期导管室接入与功能良好生存率绝对提高10%至15%相关。
  • 对标准治疗无效的室颤/无脉性室速OHCA:静脉-动脉ECMO联合冠脉造影和PCI策略下功能良好生存率9%至45%。

临床怎么用

  • 室颤/无脉性室速OHCA且复苏后ST段抬高患者应积极考虑早期冠脉造影和PCI。
  • 无ST段抬高患者早期进入心导管室可能带来功能良好生存率绝对提高10%至15%。
  • 对标准治疗无效的室颤/无脉性室速OHCA可考虑静脉-动脉ECMO支持下的冠脉造影和PCI策略。

局限性

  • 当前科学证据主要基于观察性病例系列,存在潜在混杂选择偏倚。
  • 随机临床试验尚在计划或进行中,最佳临床实践有待随机试验证据进一步明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronary artery disease is prevalent in different causes of out-of-hospital cardiac arrest (OHCA), especially in individuals presenting with shockable rhythms of ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT). The purpose of this report is to review the known prevalence and potential importance of coronary artery disease in patients with OHCA and to describe the emerging paradigm of treatment with advanced perfusion/reperfusion techniques and their potential benefits on the basis of available evidence. Although randomized clinical trials are planned or ongoing, current scientific evidence rests principally on observational case series with their potential confounding selection bias. Among patients resuscitated from VF/pVT OHCA with ST-segment elevation on their postresuscitation ECG, the prevalence of coronary artery disease has been shown to be 70% to 85%. More than 90% of these patients have had successful percutaneous coronary intervention. Conversely, among patients resuscitated from VF/pVT OHCA without ST-segment elevation on their postresuscitation ECG, the prevalence of coronary artery disease has been shown to be 25% to 50%. For these patients, early access to the cardiac catheterization laboratory is associated with a 10% to 15% absolute higher functionally favorable survival rate compared with more conservative approaches of late or no access to the cardiac catheterization laboratory. In patients with VF/pVT OHCA refractory to standard treatment, a new treatment paradigm is also emerging that uses venoarterial extracorporeal membrane oxygenation to facilitate return of normal perfusion and to support further resuscitation efforts, including coronary angiography and percutaneous coronary intervention. The burden of coronary artery disease is high in this patient population, presumably causative in most patients. The strategy of venoarterial extracorporeal membrane oxygenation, coronary angiography, and percutaneous coronary intervention has resulted in functionally favorable survival rates ranging from 9% to 45% in observational studies in this patient population. Patients with VF/pVT should be considered at the highest severity in the continuum of acute coronary syndromes. These patients have a significant burden of coronary artery disease and acute coronary thrombotic events. Evidence from randomized trials will further define optimal clinical practice.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Yannopoulos D, Bartos JA, Aufderheide TP, et al. The Evolving Role of the Cardiac Catheterization Laboratory in the Management of Patients With Out-of-Hospital Cardiac Arrest: A Scientific Statement From the American Heart Association. Circulation. 2019. PMID: 30760026. doi:10.1161/CIR.0000000000000630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。